Intercell vaccine meets bacterial infection endpoint

Intercell AG (VSE:ICLL; OTCQX:INRLY) said its IC43 vaccine met the primary endpoint of immunogenicity in a Phase II trial to vaccinate against Pseudomonas aeruginosa bacterial infections. All IC43 gr...